Ultrasensitive detection of Salmonella and Listeria monocytogenes
Researchers from the Tel Aviv University, Nemis Technologies and Biosynth Carbosynth recently reported the new AquaSpark™-based chemiluminescence probes for the ultrasensitive direct detection of viable pathogenic bacteria. This study demonstrated that the enzyme substrates could detect their corresponding bacteria with an LOD value about 600‐fold lower than that of fluorescent probes. The authors were able to detect a minimum of 10 Salmonella cells within only 6 hours incubation. Both speed and sensitivity are critical attributes of probes for the development of urgently needed detection systems for point-of-care diagnostics.
Reference: Roth‐Konforti, M. , Green, O. , Hupfeld, M. , Fieseler, L. , Heinrich, N. , Ihssen, J. , Vorberg, R. , Wick, L. , Spitz, U. and Shabat, D. (2019), Ultrasensitive Detection of Salmonella and Listeria monocytogenes by Small‐Molecule Chemiluminescence Probes. Angew. Chem. Int. Ed.. doi:10.1002/anie.201904719
Researchers from Tel Aviv University developed new reagents termed 'AquaSpark' to visually detect processes inside cells or biological samples. In contrast to luciferin or fluorescent probes, the new compounds do not require any genetic modification of cells and no excitation light source is needed. Biosynth Carbosynth received the license to manufacture the pioneering compounds and to market them in the diagnostics field.
About Biosynth Carbosynth:
Biosynth Carbosynth is the new global brand created from the merger of two key players in the fine chemicals market. The company manufactures and sources a vast range of chemical and biochemical products and specialises in carbohydrates, nucleosides, antimicrobials, APIs, enzyme substrates, natural products, and chemiluminescence-based probes. Biosynth Carbosynth and TAU are constantly developing new AquaSpark™ probes in close collaboration and are expanding the unique product range.
Incorporated in January 2018, Nemis Technologies AG is a joint-venture between Biosynth and RAMOT, the Tel Aviv University business Engagement Center established to develop rapid and innovative diagnostic test kits based on the AquaSpark™ technology jointly developed and owned by Biosynth and Ramot.
To learn more visit us at AACC, Anaheim, stand #768!